Chemotherapeutic targeting of myeloid-derived suppressor cells

Darya Alizadeh; Emmanuel Katsanis; Nicolas Larmonier

doi:10.4161/onci.27359

Chemotherapeutic targeting of myeloid-derived suppressor cells

Darya Alizadeh, Emmanuel Katsanis, Nicolas Larmonier

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.

Original language	English (US)
Article number	e27338
Journal	OncoImmunology
Volume	3
Issue number	1
DOIs	https://doi.org/10.4161/onci.27359
State	Published - 2014

Keywords

Cancer
Chemoimmunomodulation
Doxorubicin
Helper T lymphocytes
Myeloid-derived suppressor cells
ROS

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.4161/onci.27359

Cite this

@article{76e40a71c23d4daf9e63d4349cfe85b9,

title = "Chemotherapeutic targeting of myeloid-derived suppressor cells",

abstract = "Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.",

keywords = "Cancer, Chemoimmunomodulation, Doxorubicin, Helper T lymphocytes, Myeloid-derived suppressor cells, ROS",

author = "Darya Alizadeh and Emmanuel Katsanis and Nicolas Larmonier",

note = "Funding Information: Grant support came from Cancer Biology Training grant T32CA009213, NIH/NCI R01 grant CA104926, and AZ Cancer Center Support Grant CA023074.",

year = "2014",

doi = "10.4161/onci.27359",

language = "English (US)",

volume = "3",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "1",

}

TY - JOUR

T1 - Chemotherapeutic targeting of myeloid-derived suppressor cells

AU - Alizadeh, Darya

AU - Katsanis, Emmanuel

AU - Larmonier, Nicolas

N1 - Funding Information: Grant support came from Cancer Biology Training grant T32CA009213, NIH/NCI R01 grant CA104926, and AZ Cancer Center Support Grant CA023074.

PY - 2014

Y1 - 2014

N2 - Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.

AB - Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.

KW - Cancer

KW - Chemoimmunomodulation

KW - Doxorubicin

KW - Helper T lymphocytes

KW - Myeloid-derived suppressor cells

KW - ROS

UR - http://www.scopus.com/inward/record.url?scp=84899061598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899061598&partnerID=8YFLogxK

U2 - 10.4161/onci.27359

DO - 10.4161/onci.27359

M3 - Article

AN - SCOPUS:84899061598

SN - 2162-4011

VL - 3

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - e27338

ER -

Chemotherapeutic targeting of myeloid-derived suppressor cells

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this